Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bart Barlogie, Mauricio Pineda-Roman, Frits Van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, John Crowley

Research output: Contribution to journalArticlepeer-review

193 Scopus citations

Abstract

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 patients randomized to thalidomide, whereas overall survival was indistinguishable from that of the 345 patients treated on the control arm. With further follow-up currently at a median of 72 months, survival plots segregated 5 years after initiation of therapy in favor of thalidomide (P=.09), reaching statistical significance for the one third of patients exhibiting cytogenetic abnormalities (CAs; P=.02), a wellrecognized adverse prognostic feature. The duration of complete remission was also superior in the cohort presenting with CAs such that, at 7 years from onset of complete remission, 45% remained relapse-free as opposed to 20% on the control arm (P=.05). These observations were confirmed when examined by multivariate analysis demonstrating that thalidomide reduced the hazard of death by 41% among patients with CA-positive disease (P=.008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well,

Original languageEnglish (US)
Pages (from-to)3115-3121
Number of pages7
JournalBlood
Volume112
Issue number8
DOIs
StatePublished - Oct 15 2008

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities'. Together they form a unique fingerprint.

Cite this